Literature DB >> 18812519

Promyelocytic leukemia protein induces apoptosis due to caspase-8 activation via the repression of NFkappaB activation in glioblastoma.

Kazuyuki Kuwayama1, Kazuhito Matsuzaki, Yoshihumi Mizobuchi, Hideo Mure, Keiko T Kitazato, Teruyoshi Kageji, Mitsuyoshi Nakao, Shinji Nagahiro.   

Abstract

Promyelocytic leukemia (PML) protein plays an essential role in the induction of apoptosis; its expression is reduced in various cancers. As the functional roles of PML in glioblastoma multiforme (GBM) have not been clarified, we assessed the expression of PML protein in GBM tissues and explored the mechanisms of PML-regulated cell death in GBM cells. We examined the PML mRNA level and the expression of PML protein in surgical GBM specimens. PML-regulated apoptotic mechanisms in GBM cells transfected with plasmids expressing the PML gene were examined. The protein expression of PML was significantly lower in GBM than in non-neoplastic tissues; approximately 10% of GBM tissues were PML-null. The PML mRNA levels were similar in both tissue types. The overexpression of PML activated caspase-8 and induced apoptosis in GBM cells. In these cells, PML decreased the expression of transactivated forms of NFkappaB/p65, and c-FLIP gene expression was suppressed. Therefore, PML-induced apoptosis resulted from the suppression of the transcriptional activity of NFkappaB/p65. PML overexpression decreased phosphorylated IkappaBalpha and nuclear NFkappaB/p65 and increased the expression of the suppressor of cytokine signaling (SOCS-1). A proteasome inhibitor blocked the reduction of activated p65 by PML. The reduction of PML is associated with the pathogenesis of GBM. PML induces caspase-8-dependent apoptosis via the repression of NFkappaB activation by which PML facilitates the proteasomal degradation of activated p65 and the sequestration of p65 with IkappaBalpha in the cytoplasm. This novel mechanism of PML-regulated apoptosis may represent a therapeutic target for GBM.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18812519      PMCID: PMC2718984          DOI: 10.1215/15228517-2008-083

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN: 1522-8517            Impact factor:   12.300


  40 in total

Review 1.  Activators and target genes of Rel/NF-kappaB transcription factors.

Authors:  H L Pahl
Journal:  Oncogene       Date:  1999-11-22       Impact factor: 9.867

Review 2.  The transcriptional role of PML and the nuclear body.

Authors:  S Zhong; P Salomoni; P P Pandolfi
Journal:  Nat Cell Biol       Date:  2000-05       Impact factor: 28.824

3.  PML regulates p53 acetylation and premature senescence induced by oncogenic Ras.

Authors:  M Pearson; R Carbone; C Sebastiani; M Cioce; M Fagioli; S Saito; Y Higashimoto; E Appella; S Minucci; P P Pandolfi; P G Pelicci
Journal:  Nature       Date:  2000-07-13       Impact factor: 49.962

4.  PML is induced by oncogenic ras and promotes premature senescence.

Authors:  G Ferbeyre; E de Stanchina; E Querido; N Baptiste; C Prives; S W Lowe
Journal:  Genes Dev       Date:  2000-08-15       Impact factor: 11.361

5.  Inhibition of death receptor signals by cellular FLIP.

Authors:  M Irmler; M Thome; M Hahne; P Schneider; K Hofmann; V Steiner; J L Bodmer; M Schröter; K Burns; C Mattmann; D Rimoldi; L E French; J Tschopp
Journal:  Nature       Date:  1997-07-10       Impact factor: 49.962

Review 6.  Oncogenes and tumor suppressors in the molecular pathogenesis of acute promyelocytic leukemia.

Authors:  P P Pandolfi
Journal:  Hum Mol Genet       Date:  2001-04       Impact factor: 6.150

7.  Heterogeneous nuclear expression of the promyelocytic leukemia (PML) protein in normal and neoplastic human tissues.

Authors:  M Gambacorta; L Flenghi; M Fagioli; S Pileri; L Leoncini; B Bigerna; R Pacini; L N Tanci; L Pasqualucci; S Ascani; A Mencarelli; A Liso; P G Pelicci; B Falini
Journal:  Am J Pathol       Date:  1996-12       Impact factor: 4.307

8.  Embryonic lethality and liver degeneration in mice lacking the RelA component of NF-kappa B.

Authors:  A A Beg; W C Sha; R T Bronson; S Ghosh; D Baltimore
Journal:  Nature       Date:  1995-07-13       Impact factor: 49.962

9.  The PML growth-suppressor has an altered expression in human oncogenesis.

Authors:  M H Koken; G Linares-Cruz; F Quignon; A Viron; M K Chelbi-Alix; J Sobczak-Thépot; L Juhlin; L Degos; F Calvo; H de Thé
Journal:  Oncogene       Date:  1995-04-06       Impact factor: 9.867

10.  Regulation and localization of the Bloom syndrome protein in response to DNA damage.

Authors:  O Bischof; S H Kim; J Irving; S Beresten; N A Ellis; J Campisi
Journal:  J Cell Biol       Date:  2001-04-16       Impact factor: 10.539

View more
  8 in total

1.  An NF-κB p65-cIAP2 link is necessary for mediating resistance to TNF-α induced cell death in gliomas.

Authors:  Xueyan Zhao; Travis Laver; Suk W Hong; George B Twitty; Annelies Devos; Marijke Devos; Etty N Benveniste; Susan E Nozell
Journal:  J Neurooncol       Date:  2011-01-30       Impact factor: 4.130

2.  PML: An emerging tumor suppressor and a target with therapeutic potential.

Authors:  Erin L Reineke; Hung-Ying Kao
Journal:  Cancer Ther       Date:  2009-09-01

3.  NPAS3 demonstrates features of a tumor suppressive role in driving the progression of Astrocytomas.

Authors:  Frederico Moreira; Tim-Rasmus Kiehl; Kelvin So; Norbert F Ajeawung; Carmelita Honculada; Peter Gould; Russell O Pieper; Deepak Kamnasaran
Journal:  Am J Pathol       Date:  2011-05-19       Impact factor: 4.307

Review 4.  The Role of Metabolic Plasticity in Blood and Brain Stem Cell Pathophysiology.

Authors:  Catherine J Libby; Jonathan McConathy; Victor Darley-Usmar; Anita B Hjelmeland
Journal:  Cancer Res       Date:  2019-10-01       Impact factor: 12.701

5.  Akt2 and Akt3 play a pivotal role in malignant gliomas.

Authors:  Hideo Mure; Kazuhito Matsuzaki; Keiko T Kitazato; Yoshifumi Mizobuchi; Kazuyuki Kuwayama; Teruyoshi Kageji; Shinji Nagahiro
Journal:  Neuro Oncol       Date:  2009-12-21       Impact factor: 12.300

6.  TRIM22 inhibits the TRAF6-stimulated NF-κB pathway by targeting TAB2 for degradation.

Authors:  Hui Qiu; Fang Huang; Han Xiao; Binlian Sun; Rongge Yang
Journal:  Virol Sin       Date:  2013-06-26       Impact factor: 4.327

7.  SOCS5 contributes to temozolomide resistance in glioblastoma by regulating Bcl-2-mediated autophagy.

Authors:  Jie Yu; Lin Han; Feng Yang; Mingliang Zhao; Hong Zhou; Linwang Hu
Journal:  Bioengineered       Date:  2022-06       Impact factor: 6.832

8.  lncRNA-PLACT1 sustains activation of NF-κB pathway through a positive feedback loop with IκBα/E2F1 axis in pancreatic cancer.

Authors:  Xiaofan Ren; Changhao Chen; Yuming Luo; Mingyang Liu; Yuting Li; Shangyou Zheng; Huilin Ye; Zhiqiang Fu; Min Li; Zhihua Li; Rufu Chen
Journal:  Mol Cancer       Date:  2020-02-21       Impact factor: 27.401

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.